A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B

Trial Profile

A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs ABI-H0731 (Primary) ; Entecavir; Peginterferon alfa-2a; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Assembly Biosciences
  • Most Recent Events

    • 02 Jan 2018 Planned number of patients changed from 80 to 84.
    • 02 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
    • 02 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top